Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Tag: AD109 aroxybutynin atomoxetine
Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Read More
Enrollment Completed Early for Phase 3 Trial of Oral Sleep Apnea Pill
Apnimed announced the early completion of enrollment for its phase 3 trial to evaluate the efficacy and safety of AD109 for obstructive sleep apnea.
Read More
FDA Grants Fast Track Designation to Apnimed Sleep Apnea Drug Candidate AD109
The US FDA has granted Fast Track designation for Apnimed’s oral pharmacologic AD109 for the treatment of obstructive sleep apnea (OSA).
Read More